Endocrine Testing for Infertility Market Research Report - Segmentation by Test Type (Estradiol Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Progesterone Test, Prolactin Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Others); Technology (Chromatography, Immunoassay, Mass Spectroscopy, Others); End User (Clinical Laboratories, Diagnostic Centers, Hospitals, Others); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-15163
Format:
Region: Global
Chapter 1. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-110 Impact Analysis
2.3.1. Impact during 2023 – 2030
2.3.2. Impact on Supply – Demand
Chapter 3. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET - Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET – By Product & Service
6.1 Reagents & Kits
6.2. Instruments
6.3. Data Management Software
6.4. Service
Chapter 7. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET– By Technology
7.1. Clinical Microbiology
7.2. DNA Microassay
7.3. Immunoassay
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Polymerize Chain Reaction (PCR)
7.6. Others
Chapter 8. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET - By Application
8.1. Academic & Research Institutions
8.2. Diagnostic Centers
8.3. Hospitals & Clinical Laboratories
8.4. Others
Chapter 9. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET – By Region
9.1. North America
9.2. Europe
9.3.The Asia Pacific
9.4.Latin America
9.5. Middle-East and Africa
Chapter 10. INFECTIOUS DISEASE RAPID DIAGNOSTIC TESTING FOR HPV MARKET– Company Profiles – (Overview, Product Portfolio, Financials, Developments)
10.1. QIAGEN (Germany)
10.2. Abbott Laboratories (United States)
10.3. Becton, Dickinson, and Company (United States)
10.4. Fast Track Diagnostics (Luxembourg)
10.5. Thermo Fisher Scientific Inc. (United States)
10.6. Bio-Rad Laboratories, Inc. (United States)
10.7. Cepheid Inc. (United States)
10.8. Roche Holding AG (Switzerland)
10.9. Hologic, Inc. (United States)
10.10. GenMark Diagnostics, Inc. (United States)
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
Global Endocrine Testing for Infertility Market is estimated to be worth USD 294.43 Million in 2022 and is projected to reach a value of USD 557.61 Billion by 2030, growing at a CAGR of 8.31% during the forecast period 2023-2030.
The Global Endocrine Testing for Infertility Market Drivers is the declining fertility rate and the increasing WHO initiative towards fertility care.
Based on the Test Type, the Global Endocrine Testing for Infertility Market is segmented into Estradiol Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Progesterone Test, Prolactin Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, and Others.
The United States is the most dominating country in the region of North America for the Global Endocrine Testing for Infertility Market.
Agilent Technologies, Abbott Laboratories, and LabCorp are the leading players in the Global Endocrine Testing for Infertility Market.
